clellandlab.bsky.social @clellandlab.bsky.social · 02/12/2025We weigh risks vs. benefits in fatal diseases—waiting for perfection shouldn’t delay life-saving therapies. Our framework guides research on CRISPR off-targets and clinical decisions. Congrats to Ariella Angelini Stewart on her first, first-author publication! www.nature.com/articles/s41... 030